Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia

Psychiatry Research

Volumn 196, Issue 2-3, 2012, Pages 201-206

  Tang, Bin ^a   Capitao, Cristina ^a   Dean, Brian ^b,c   Thomas, Elizabeth A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Celecoxib; COX 2; Inflammation; Microarray; Prostaglandin; Psychiatric disorder

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; PROSTAGLANDIN ENDOPEROXIDE RECEPTOR 3; RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALOX5 GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COX1 GENE; COX2 GENE; CYP19A1 GENE; CYP1B1 GENE; CYP2D6 GENE; CYP4A11 GENE; CYP4Z1 GENE; DRUG EFFECT; GENE; GENE EXPRESSION; HUMAN; INFLAMMATION; PLA2G12A GENE; PLA2G4C GENE; PLA2G5 GENE; PLA2G6 GENE; PRIORITY JOURNAL; PTGER3 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIPSYCHOTIC AGENTS; ARACHIDONIC ACID; COHORT STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RNA, MESSENGER; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84861454941     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.09.026     Document Type: Article

References (38)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 2007, 90:179-185.
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53:56-64.
3. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neuroscience Letters 1999, 271:126-128.
4. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Progress in Neurobiology 2005, 76:77-98.
5. Chakraborti A.K., Garg S.K., Kumar R., Motiwala H.F., Jadhavar P.S. Progress in COX-2 inhibitors: a journey so far. Current Medicinal Chemistry 2010, 17:1563-1593.
6. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. The International Journal of Neuropsychopharmacology 2011, 14:997-1012.
7. Desplats P.A., Kass K.E., Gilmartin T., Stanwood G.D., Woodward E.L., Head S.R., Sutcliffe J.G., Thomas E.A. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. Journal of Neurochemistry 2006, 96:743-757.
8. Gattaz W.F., Kollisch M., Thuren T., Virtanen J.A., Kinnunen P.K.J. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biological Psychiatry 1987, 22:421-426.
9. Goldman-Rakic P.S., Seleman L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bulletin 1997, 23:437-458.
10. Kaiya H., Uematsu M., Ofuji M., Nishida A., Takeuchi K., Nozaki M., Idaka E. Elevated plasma prostaglandin E2 levels in schizophrenia. Journal of Neural Transmission 1989, 77:39-46.
11. Kemperman R.F., Veurink M., van der Wal T., Knegtering H., Bruggeman R., Fokkema M.R., Kema I.P., Korf J., Muskiet F.A. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2006, 74:75-85.
12. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences 2009, 63:257-265.
13. Muller N., Dursun S.M. Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now? 2010, Journal of Psychopharmacology.
14. Muller N., Riedel M., Ackenheil M., Schwarz M.J. The role of immune function in schizophrenia: an overview. European Archives of Psychiatry and Clinical Neuroscience 1999, 249(Suppl. 4):62-68.
15. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Moller H.J., Schwarz M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. The American Journal of Psychiatry 2002, 159:1029-1034.
16. Muller N., Ulmschneider M., Scheppach C., Schwarz M.J., Ackenheil M., Moller H.J., Gruber R., Riedel M. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry and Clinical Neuroscience 2004, 254:14-22.
17. Nakanishi Y., Nakatsuji M., Seno H., Ishizu S., Akitake-Kawano R., Kanda K., Ueo T., Komekado H., Kawada M., Minami M., Chiba T. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011, 32:1333-1339.
18. Narayan S., Kass K., Thomas E.A. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. Journal of Neuroscience Research 2006, 85:757-765.
19. Narayan S., Tang B., Head S.R., Gilmartin T.J., Sutcliffe J.G., Dean B., Thomas E.A. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Research 2008, 1239:235-248.
20. Nogawa S., Zhang F., Ross M.E., Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. Journal of Neuroscience 1997, 17:2746-2755.
21. Phillis J.W., Horrocks L.A., Farooqui A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Research Reviews 2006, 52:201-243.
22. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
23. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. Journal of Neuropathology and Experimental Neurology 2000, 59:137-150.
24. Rapaport M.H., Delrahim K.K., Bresee C.J., Maddux R.E., Ahmadpour O., Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biological Psychiatry 2005, 57:1594-1596.
25. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophrenia Bulletin 2004, 30:901-911.
26. Riedel M., Strassnig M., Schwarz M.J., Muller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 2005, 19:805-819.
27. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcuim-independent phospholipase A2. Archives of General Psychiatry 1997, 54:487-494.
28. Ross B.M., Turenne S., Moszczynska A., Warsh J.J., Kish S.J. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Research 1999, 821:407-413.
29. Skosnik P.D., Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2003, 69:367-384.
30. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., Bogerts B. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathologica 2006, 112:305-316.
31. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. Journal of Immunology 2000, 164:361-370.
32. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. Journal of Autoimmunity 2006, 27:71-80.
33. Tang B., Chang W.L., Lanigan C.M., Dean B., Sutcliffe J.G., Thomas E.A. Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell 2009, 8:339-342.
34. Torkamani A., Dean B., Schork N.J., Thomas E.A. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Research 2010, 20:403-412.
35. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biological Psychiatry 2008, 64:820-822.
36. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophrenia Research 2000, 42:7-17.
37. Yermakova A., O'Banion M.K. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Current Pharmaceutical Design 2000, 6:1755-1776.
38. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clinical Microbiology Reviews 1995, 8:131-145.